31년 2023월 XNUMX일 마감된 연도의 결과
The information contained within this announcement was deemed by Deltex Medical Group PLC to constitute inside information as stipulated under the UK Market Abuse Regulation
월 28 2024
델텍스 메디컬 그룹 PLC
("Deltex Medical" 또는 "그룹")
31년 2023월 XNUMX일 마감된 연도의 결과
Deltex Medical Group plc (AIM: DEMG) today announces its results for the year ended 31 December 2023.
하이라이트
재정상의
? Successfully completed the restructuring of the business and achieved annualised cost savings of approximately £1.0 million
? Revenues of £1.8 million (2022: £2.5 million), primarily reflecting the impact from unexpected delays in releasing the new TrueVue monitor and difficult market conditions
? £(0.9) 백만의 조정 EBITDA(2022: £(0.6) 백만)
? £1.89 million fundraise completed in August 2023 with net proceeds successfully used to strengthen the balance sheet and implement the Group's restructuring plan
? Achieved a 31% reduction in overheads (excluding exceptional costs) to £2.0 million (2022: £2.9 million). The annualised reduction in overheads is expected to be c. £1 million
? Gross cash expenditure on research and product development by the Group (excluding the effect of grants or capitalisation of product development) amounted to £0.6 million (2022: £0.8 million). The net amount, having taken into account grants, was £0.4 million (2022: £0.7 million).
? Cash in hand at 31 December 2023 of £0.7 million (2022: £0.5 million)
비즈니스/상업 활동
? 신제품 출시 TrueVue monitor in the UK and the EU with encouraging interest levels from existing legacy monitor users and orders now increasing, suggesting a large potential replacement market
? Markets in the Middle East, Asia and South America also being targeted for the new TrueVue monitor where Europe's CE mark is recognised, with preparatory work also underway for local regulatory approvals
? Work started on the FDA 510(k) premarket regulatory filing for the new TrueVue monitor which, when approved, will enable sales into the USA which are expected to start in 2025
? Good progress in securing production efficiencies associated with the manufacture of the new TrueVue 모니터
? Ongoing successful development work on a new non-invasive Doppler-based haemodynamic monitoring device incorporating Deltex Medical's core oesophageal doppler monitoring ("ODM") technology with a substantial addressable market
? Implementation of new lower cost and more efficient digital marketing strategies in line with the Group's new "zero-based budgeting" approach
? Have met the operational and internal financial targets agreed by the Board for the first quarter and the outlook is positive
Commenting on the results, Nigel Keen, Chairman of Deltex Medical, 말 :
"2023 was a difficult year for the Group; however, we have successfully refinanced the business and reduced our cost base substantially and I am pleased to be able to report that 2024 has started well."
"We also launched the new TrueVue monitor and see a significant upgrade and replacement market."
"Good progress is being made on a new, easy-to-use non-invasive device which sits on the same platform as Deltex Medical's core ODM technology."
자세한 내용은 문의하시기 바랍니다 :
델텍스 메디컬 그룹 PLC | + 01243 774 837 |
나이젤 킨 회장 | |
앤디 미어스, CEO | |
Natalie Wettler, 그룹 재무 이사 | |
| |
Allenby Capital Limited - 추천 고문 및 Broker | + 020 3328 5656 |
Jeremy Porter / Vivek Bhardwaj(기업 금융) | |
Tony Quirke / Stefano Aquilino(영업 및 기업 중개) |
편집자 참고 사항
델텍스메디칼의 기술력
Deltex Medical의 TrueVue 시스템은 독점적인 혈류역학 모니터링 기술을 사용하여 임상의가 환자의 결과를 개선하고 병원의 처리량과 용량을 늘릴 수 있도록 지원합니다.
Deltex Medical은 전 세계에서 수행된 상당한 수의 임상시험에서 동료 심사를 거쳐 발표된 증거의 고유한 조직을 구축하기 위해 장기적으로 투자했습니다. 이 연구는 환자 처리량을 늘리고 병원 용량을 확장함으로써 환자와 병원 시스템 모두에 혜택을 제공하는 임상 결과에서 통계적으로 유의미한 개선을 보여줍니다.
그룹의 주력 제품이자 세계 최고의 초음파 기반 식도 도플러 모니터링("ODM")은 마취된 환자를 대상으로 실시된 24건의 무작위 대조 시험을 통해 지원됩니다. 결과적으로 ODM의 주요 적용 분야는 선택적 수술을 받는 환자를 위한 치료 안내에 초점을 맞추고 있지만, 중환자실에서 진정된 환자는 여전히 우리 사업에서 중요한 부분을 차지합니다. 그룹의 새로운 차세대 모니터는 ODM 기술의 사용을 보다 직관적으로 만들고 각 환자의 상태에 대한 증강 데이터를 제공합니다.
Deltex Medical의 엔지니어 및 과학자들은 영국 국립 물리 연구소("NPL")와 함께 성공적인 연구를 수행하여 그룹의 '표준' ODM 기술을 확장하고 개발하여 완전히 비침습적으로 사용할 수 있도록 했습니다. 이로써 비진정 환자에 대한 Deltex Medical의 기술 적용이 크게 확대될 것입니다. 새로운 차세대 모니터에 출시될 이 새로운 기술 향상은 그룹의 혈류역학 모니터링 기술에 대한 시장을 상당히 확대할 것이며 오랜 기간 확립된 ODM 증거 기반을 보완합니다.
Deltex Medical의 새로운 비침습 기술은 다음과 같은 다양한 의료 환경에서 사용할 수 있는 잠재적인 응용 프로그램을 가지고 있습니다.
§ 패혈증의 발견 및 진단을 포함하여 환자의 신속한 분류를 위한 사고 및 응급;
§ 일반적으로 병동은 상태가 빠르게 악화될 수 있는 환자를 위한 실시간 데이터 기반 치료 체계를 용이하게 합니다. 그리고
§ 중환자실에서 더 이상 진정제나 삽관을 하지 않는 수술 후 환자를 정기적으로 모니터링할 수 있습니다.
그룹의 주요 기회 중 하나는 병원 전체에서 사용할 수 있는 이 새로운 비침습적 기술을 포지셔닝하는 것입니다. Deltex Medical의 혈류역학 모니터링 기술은 임상의에게 환자의 순환 혈액량과 심장 기능에 대한 박동 간 실시간 정보를 제공합니다. 이 정보는 임상의가 환자에게 유체 및 약물 전달을 모두 최적화할 수 있도록 하는 데 중요합니다.
Deltex Medical의 비즈니스 모델은 TrueVue 시스템에 사용되는 일회용 ODM 프로브 판매와 관련된 반복 수익을 창출하고 그룹의 새로운 비침습 기술에서 파생되는 새로운 증분 수익원으로 이러한 수익을 보완하는 것입니다. .
기존 일회용 ODM 프로브와 새로운 비침습적 장치는 모두 2023년 XNUMX월 시장에 출시된 동일한 새로운 TrueVue 모니터에 연결됩니다. 모니터는 판매되거나 병원의 자본 조달 시간이 길어지는 경우가 많습니다. 그룹 기술의 빠른 채택을 장려하기 위해 항목을 대여할 수 있습니다.
델텍스메디컬 고객 여러분
Deltex Medical 제품의 주요 사용자는 현재 병원 수술실에서 근무하는 마취과 전문의와 ICU에서 근무하는 중환자실 전문의입니다. 이 고객 프로필은 그룹의 새로운 비침습적 기술이 시장에 채택됨에 따라 변경될 것입니다. 영국에서 그룹은 NHS에 직접 판매합니다. 미국에서 그룹은 다양한 병원 시스템에 직접 판매합니다. 그룹은 또한 유럽 연합, 아시아 및 미주 지역의 40개 이상의 국가에서 유통업체를 통해 제품을 판매합니다.
델텍스메디칼의 목표
최소 침습 기술과 비침습 기술로 구성된 Deltex Medical의 새로운 TrueVue 모니터가 전 세계 모든 병원 환경에서 신생아부터 성인, 깨어 있거나 마취 상태인 모든 환자에 대한 혈역학적 모니터링의 표준으로 채택되는 것을 확인하는 것입니다.
자세한 내용은 다음으로 이동하십시오. www.deltexmedical.com
의장 성명서
개요
We are pleased to report that we successfully completed the restructuring of the Group's business as well as achieving annualised cost savings of approximately £1.0 million. We have since met the operational and internal financial targets agreed by the Board for the first quarter of the year and the outlook is positive.
Notwithstanding 2023 initially being a difficult year for Deltex Medical, 2023 saw a number of key milestones achieved by the Group, including the successful turnaround of the business.
Deltex Medical faced three principal challenges which together contributed to the Group needing to carry out a fundraise, details of which were announced by Deltex Medical on 14 July 2023 (the "Fundraise"). These challenges comprised:
§ a continuing slow pick-up in activity levels post the end of the Covid-19 pandemic;
§ extended lead times for certain specific components needed to complete the new TrueVue monitor development, largely related to post Covid-19 supply chain issues. This resulted in the slippage of the launch date for the new TrueVue monitor; and
§ delays in orders and the award of a national tender for haemodynamic monitoring with one of the Group's Latin American distributors which had been expected to have strong short-term prospects for cash generation.
The Fundraise has enabled the Group to turnaround its business with the result that:
§ the cost base of the Group has been significantly reduced, bringing down the cashflow breakeven point substantially;
§ lower cost and more efficient digital marketing techniques have been adopted which are expected to help drive incremental revenues albeit with smaller salesforces in the UK and USA; and
§ 새로운 TrueVue monitor was completed and launched in the UK and Europe, as well as global markets that recognise the EU's 'CE mark', in November 2023.
Since its launch, a number of existing users of the Group's oesophageal Doppler monitoring technology have shown strong levels of interest in the new TrueVue monitor with orders now increasing. In parallel, good progress has been made by the Group in relation to streamlining the manufacturing processes associated with the new monitor.
재정상의 결과
Group revenues for the year ended 31 December 2023 decreased by 28% to £1.8 million (2022: £2.5 million) primarily reflecting difficult market conditions and the delayed launch to the new TrueVue 감시 장치. These issues collectively adversely affected the sales of the Group's single-use disposable ODM probes which declined to £1.4 million (2022: £1.8 million).
As a proportion of total Group revenues, direct sales into the USA and UK remained broadly unchanged at 50% (2022: 51%).
Deltex Medical's European customers have been aware of the expected launch of the new TrueVue monitor and during the year became increasingly reluctant to purchase the previous generation monitor. As a result, monitor revenues reduced by 52% to £258,000 (2022: £537,000).
The reduction in activity levels also adversely affected overhead recovery in the Chichester production facility, resulting in the Group's gross margin reducing 63%(2022년: 74%).
Overheads, excluding exceptional costs, 31 감소% to £2.0 million (2022: £2.9 백만).
The exceptionals of £366,000 largely related to restructuring costs, namely reducing the Group's headcount, including payments in lieu of notice, redundancy costs and associated legal fees. In addition, £141,000 was associated with writing off research and development projects not taken forward.
Adjusted EBITDA (comprising earnings before interest, tax, depreciation and amortisation, share-based payments and non-executive directors' fees) was a loss of £(860,000) (2022: £(607,000)). Adjusted EBITDA is reconciled to operating loss in note 3.2 금융의 진술.
Gross cash expenditure on research and product development by the Group (excluding the effect of grants or capitalisation of product development) amounted to £0.6 million (2022: £0.8 million). The net amount, having taken into account grants, was £0.4 million (2022: £0.7 million). This year-on-year reduction reflects that the majority of the costs for the development work on the new TrueVue monitor were incurred before 2023.
Operating loss for the year was £(1.1) million (2022: £(0.9) million). Loss for the year was £(1.3) million (2022: £(1.1) million).
31년 2023월 0.7일 현재 보유 현금은 2022만 파운드(0.5년: XNUMX만 파운드)였습니다.
근무지에서 발생 방과 후 액티비티
Deltex Medical sells directly, via its own sales teams, into UK and US hospitals, and via a network of distributors into approximately 40 other international territories.
The Group's direct sales teams continue to experience constraints in being able to access clinicians in UK and US hospitals' operating theatres ("ORs") and intensive care units ("ICUs"). These constraints were imposed by UK and US hospitals during the Covid-19 pandemic, and many of these constraints remain in place notwithstanding the end of the pandemic.
Despite 2023 being a challenging year for the Group, progress was made on a number of fronts including:
§ the launch of the new monitor;
§ development work on the new, novel non-invasive device;
§ a substantial reduction in costs - leading to a significantly lower breakeven point; and
§ improved marketing following adoption of new digital techniques.
These items are more fully described in the accompanying Business Review.
The Board remains focussed on the importance of cash generation. Accordingly, Deltex Medical's business development activities are increasingly focused on ensuring significant incremental increases in revenues from a small number of existing and targeted prospective customers.
교직원
On behalf of the Board, I would like to thank all of the Group's employees for their hard work during what was a challenging and at times stressful year.
I would also like to thank Julian Cazalet, Mark Wippell and Tim Irish who retired as non-executive directors of the Group on 1 December 2023. Together they have been a source of invaluable wise counsel and sound advice over a number of years.
We were separately delighted to welcome Ben Carswell to the Board on 1 December as a non-executive director.
현재 거래 및 전망
XNUMXD덴탈의 launch of the new, next generation TrueVue monitor is a key milestone for the Group, with the first sale of the new TrueVue monitor having taken place at the end of November 2023.
We are seeing encouraging levels of interest in this product from the UK and our international distributors. Work has already started on the FDA 510(k) premarket regulatory submission to the US Food and Drug Administration (the "FDA") which, once regulatory approval has been received, will enable us to sell the new monitor into the US market.
We are continuing to drive forwards the development of our new non-invasive device. We believe the new device will be used in clinical areas not served well by our existing products and will therefore allow us to sell into significantly larger markets.
We continue to focus on optimising the commercial opportunities associated with a small number of significant tenders, including in Latin America, where we believe that Deltex Medical's ODM technology has strong opportunities to take market share.
After a tough 2023, I am pleased to be able to report that 2024 has started well and we are much encouraged for the future.
나이젤 날카로운
의장
월 27 2024
경영 검토
살펴보기
Deltex Medical is a world leader in high accuracy oesophageal Doppler monitoring, via its TrueVue platform, which allows real-time monitoring by clinicians of a patient's haemodynamic status.
More than twenty peer-reviewed, randomised controlled trials have demonstrated that an ODM-driven haemodynamic protocol can result in statistically significant reductions in post-operative complications such as acute kidney injuries, resulting in lower costs for hospitals due to shorter patient length-of-stay. The use of the ODM technology is good for patients. It also increases throughput and capacity for hospitals, which should help reduce the backlog in elective surgery, which is a particular issue in the United Kingdom.
Deltex Medical's technology was originally developed in a London ICU to assist with the treatment of acutely unwell critical care patients. Over time demand for the Group's high fidelity ODM-based haemodynamic monitoring technology has migrated from the ICU to the OR, particularly for complex elective surgical procedures; however, there are now signs of increasing interest from ICUs in the ODM technology.
Before the Covid-19 pandemic, approximately 80% of the Group's revenues were associated with elective surgical procedures in ORs. The near-complete cessation of elective surgery during the pandemic was highly disruptive to Deltex Medical's commercial activities, particularly in the UK and the USA, where the Group sells its technology to hospitals directly.
이기는 하지만, 포스트pandemic, elective surgery has restarted around the world, 의료 기기 sales teams, including Deltex Medical's, are still experiencing more restricted levels of access to ORs and ICUs than they enjoyed pre-pandemic.
신제품 출시 TrueVue 모니터
After a number of years in development, the Group released its new TrueVue monitor onto the market in November 2023. The development of the new device had taken longer than expected as a result of disrupted supply chains during, and for some time after, the Covid-19 pandemic.
The new monitor has been designed to act as a platform for a range of complementary technologies, including a new, novel non-invasive device that the Group is also developing.
Orders for the new TrueVue monitor are increasing which is encouraging. There is a substantial domestic and international replacement and upgrade market, which it is anticipated will drive orders in the short to medium term. In addition, the Group expects to see probe orders increasing based on new monitor equipment sales.
새로운 TrueVue monitor has been designed with production engineering input in order to reduce the prime costs of the equipment as well as enhance its overall reliability. Good progress has been made with reducing the labour hours required for each of the sub-assemblies as the Group streamlines its manufacturing processes. Overall, the gross margin on the new TrueVue monitor is expected to be higher than the previous unit, although price points vary significantly between direct sales into the UK (as well as, post launch, the USA) and overseas sales to distributors.
Work has started on assembling the necessary documents required for the 510(k) premarket regulatory submission to the US FDA. It is planned that the FDA filing process should be completed in 2025 and sales of the new monitor into the US market should follow shortly thereafter.
비침습적 장치
Deltex Medical's current ODM device is principally used on sedated patients: typically those admitted to ICUs or being operated on within ORs. The resultant haemodynamic data derived from the ODM technology is extremely accurate and has been shown in some 24 published randomised controlled trials to be associated with significantly improved patient outcomes and reduced costs to hospitals as a result of shorter hospital stays. However, limiting the use of this technology just to patients in ICUs and ORs self-evidently reduces the size of the addressable market and constrains the Group's revenues.
The new non-invasive Doppler-based haemodynamic monitoring device that the Group is developing is designed to use the same underlying oesophageal Doppler haemodynamic monitoring technology which is supported by a large body of published literature. However, a different, novel design will enable the technology to be used non-invasively and thus on a much larger patient population.
Although this new non-invasive device is still in the development phase, the Group is working on the basis that it should ultimately end up representing a form of digital haemodynamic stethoscope. This will give healthcare workers, from doctors to nurses across a range of departments, immediate access to high quality, real time haemodynamic data for patients. In turn, these data are anticipated to give rise to improved and more rapid treatment of patients throughout a hospital or other clinical care-giving facility such as the emergency services or a primary care doctor's office.
Deltex Medical believes that this new, non-invasive device, with a substantially larger addressable market, represents a significant opportunity for the Group to drive substantial profitable growth.
In parallel with working on the technical development aspects of this new, novel non-invasive technology, Deltex Medical is carrying out structured 'voice of the customer' discussions with prospective hospital-based users to determine how best to launch, and charge for, this new non-invasive ODM technology. Discussions with a number of the Group's international distributors suggest that there could be significant overseas market demand when this new device is launched.
Three principal divisions: UK, USA and 국제 노동자 동맹
Deltex Medical의 상업적 활동은 XNUMX개 부서로 구성되어 있습니다. 미국과 국제.
The Group has faced difficulties in driving its commercial activities back to those levels seen pre the Covid-19 pandemic in its two direct sales territories of the UK and the USA. Many hospitals have imposed significant restrictions on salespersons or clinical educators accessing ORs or ICUs. Once any hospital stops using Deltex Medical's ODM technology, it can take time and significant resources to re-instigate the use of the technology as the clinical staff change rapidly and new staff need to be trained on the use of ODM.
Deltex Medical has also been restricting expenditure on sales and marketing activities in the UK and USA in advance of the launch of the new monitor.
One way in which the Group has been seeking to mitigate the impact of its reduced sales and marketing spend, as well as the impact of greater restrictions on sales teams meeting hospital-based decision-makers in person, is by increasing the use of digital marketing materials. The Group is adopting a number of digital marketing techniques as well as training via the launch of its online Deltex Medical Academy.
The Group monitors closely per user probe revenues. Internal analyses demonstrate that only small increases in per (hospital) account probe purchases, or the successful adoption of the ODM technology by a small number of new, high-volume users, should drive the Group to positive cashflow.
There remains a substantial, and increasing, backlog in elective surgery as a result of the Covid-19 pandemic. In the UK the adverse effects of this backlog on patients have been exacerbated by a number of strikes by NHS healthcare workers. This backlog represents both an opportunity and a challenge for the Group. For example, there are powerful arguments, supported by the published evidence base, that the use of Deltex Medical's TrueVue technology increases patient throughput in a hospital and improves patient outcomes, thereby helping to reduce the size (and associated cost) of the backlog. Conversely, there is some anecdotal evidence that certain NHS hospitals, under pressure to reduce the backlog, are reluctant to promote the adoption of new and/or different technologies.
Following the launch of the new TrueVue monitor, Deltex Medical has now notified all UK hospitals that the previous legacy version (CardioQ-ODM+) is now obsolete. The Group has a regulatory requirement to provide service support to maintain these devices for ten years. Many NHS hospitals with the previous monitor are expected to apply for funding from capital replacement programmes to purchase the new monitor.
As it will take some time to complete the submissions required to receive FDA approval for the new TrueVue monitor, the Group's US operation has been tasked with supporting as many existing customers as possible in order to drive up probe sales, whilst cultivating these existing relationships in advance of the launch of the new TrueVue monitor into the US market, which is expected to be next year.
The International division, with its team of some 40 overseas distributors, continues to represent an important route to market for the Group's products. International sales represent approximately half of the Group's revenues.
In the first quarter of 2024, the new TrueVue monitor has been demonstrated at three large international medical exhibitions. Deltex Medical attended Arab Health in January 2024, which is now one of the largest medical device exhibitions worldwide, where it also met with a number of its distributors. Deltex Medical also attended the Korea International Medical & Hospital Equipment Show (KIMES) in Seoul, as historically the legacy monitor sold well in South Korea.
Earlier this month, the Group exhibited at the World Congress of Anaesthesia (WCA) in Singapore which is held every four years. The advantages of using Deltex Medical's technology were presented at the WCA by a clinician who presented data that demonstrated that the ODM technology should be used on young fit patients; and not just sick elderly patients.
Although the Latin American contract that the Group was awarded last year has not developed as rapidly as was first expected, there are encouraging signs that over the next couple of years this contract will be an important source of revenues to Deltex Medical. In this respect, it is encouraging that some hospitals in that market have already started to purchase probes that are linked to this contract.
Product development and 혁신
During 2023, the research and development team were focussed on completing the development of the new TrueVue monitor. This included the completion of complex and onerous regulatory testing, including electromagnetic compatibility (EMC) testing.
Notwithstanding that the successful development of the new monitor was the Group's priority, research work also continued on the development of the new, novel non-invasive haemodynamic monitoring technology, including the integration of the recommendations of the National Physical Laboratory arising from Deltex Medical's collaborative research work with them.
In addition to the development work on the new non-invasive device, work continues in relation to supporting the launch of the new TrueVue monitor.
규제
Deltex Medical designs and manufactures Class II medical devices which it sells around the world. As a result, its business activities can be significantly affected by changes to regulations. The post-Brexit regulatory regime in the UK, as well as for UK companies selling into Europe, is still evolving and the Group keeps actual or prospective changes in applicable regulations under close scrutiny.
In Europe the transition from the Medical Device Directive to the European Medical Device Regulation ("MDR") has been deferred until 2028. Although this reduces some regulatory-associated complexity in the short term, there is still considerable uncertainty as to what steps will be required, and by when, for a Class II medical device manufacturer to comply with MDR in the future.
Investment in the Group's regulatory activities remains an important part of the business and is critical for its future success.
결론
Completion of the new TrueVue monitor 이 greatly enhanced Deltex Medical's technological offering to the market as well as opening up the possibility to use this instrument as a platform for further product line extensions. We are particularly interested in the commercial potential, and significantly larger addressable market, associated with the easier-to-use non-invasive haemodynamic monitoring technology which we are 개발 중.
Initial market feedback and demand for the new monitor has been encouraging, both from existing and prospective customers. We see its launch as a critical building block in driving up probe revenues across all three of the Group's divisions.
Our key challenge is to commercialise the Group's new technologies successfully from our significantly lower cost base by maximising the use of digital marketing. As we start to generate cash, we will be able to initiate further sales initiatives to drive up revenues.
We are pleased with the progress that we have made to date in 2024.
앤디 미어스
최고 경영자
월 27 2024
연결포괄계산서 수입
31 월 XNUMX 일 종료 연도 2023
| 2023 £'000 | 2022 £'000 | |
수익 |
| 1,776 | 2,482 |
비용 판매 |
| (651) | (643) |
심한 이익 | 1,125 | 1,839 | |
행정 경비 | (1,081) | (1,560) | |
판매 및 유통 경비 | (685) | (1,027) | |
Research and Development, Quality and 규제 | (217) | (231) | |
Impairment loss on trade 채권 예외적인 비용 |
| - | (39) - |
금액 비용 |
| (2,349) | (2,857) |
기타 이득 |
| 172 | 71 |
운영 오프 | (1,052) | (947) | |
재무 비용 |
| (230) | (199) |
이전 손실 과세 | (1,282) | (1,146) | |
Tax credit on 오프 |
| - | 1 |
손실 year | (1,282) | (1,145) | |
기타 종합 비용 | |||
이익 또는 손실: Net translation differences on overseas 자회사 |
5 |
35 | |
Other comprehensive expense for the year, net of 세 | 5 | 35 | |
총포괄손실 year | (1,277) | (1,110) | |
Total comprehensive loss for the year attributable 받는 사람 : | |||
소유자 부모의 | (1,252) | (1,114) | |
비 통제 이해 | (25) | 4 | |
(1,277) | (1,110) | ||
주당 손실 - 기본 및 희석 된 |
|
(0.11p) |
(0.17p) |
Consolidated balance 시트 | |||
31월 XNUMX일 현재 2023 회사 번호 03902895 | |||
| 2023 | 2022 | |
£'000 | £'000 | ||
자산 | |||
비유류 자산 | |||
재산, 식물 및 장비 |
| 198 | 269 |
만질 수 없는 자산 |
| 3,965 | 3,769 |
총 비유동 자산 | 4,163 | 4,038 | |
Current 자산 | |||
재고 |
| 716 | 821 |
거래 채권 |
| 177 | 456 |
상각후 금융자산 비용 |
| - | 15 |
기타 전류 자산 |
| 87 | 140 |
현재 소득세 회복 가능한 | 84 | 72 | |
현금 및 현금 등가물 | 705 | 471 | |
총 전류 자산 | 1,769 | 1,975 | |
금액 자산 | 5,932 | 6,013 | |
부채 | |||
Current 부채 | |||
차입금 |
| (79) | (935) |
무역 및 기타 미지급금 |
| (855) | (1,540) |
총 전류 부채 | (934) | (2,475) | |
비유류 부채 | |||
차입금 |
| (1,665) | (1,069) |
무역 및 기타 미지급금 |
| (119) | (177) |
식량 |
| (71) | (64) |
총 비유동 부채 | (1,855) | (1,310) | |
금액 부채 | (2,789) | (3,785) | |
그물 자산 | 3,143 | 2,228 | |
공평 | |||
공유 자본 |
| 7,204 | 6,990 |
공유 프리미엄 |
| 35,650 | 33,672 |
자본 상환 비축 |
| 17,476 | 17,476 |
기타 비축 |
| 473 | 527 |
번역 비축 |
| 173 | 168 |
전환대출 어음 비축 |
| 82 | 82 |
누적 된 사상자 수 |
| (57,769) | (56,566) |
소유자에게 귀속되는 지분 부모의 | 3,289 | 2,349 | |
비 통제 이해 | (146) | (121) | |
금액 공평 | 3,143 | 2,228 |
*Prior year restatement relates to an offset of a debtor and creditor balance
|
주식 자본 |
프리미엄 공유 | 자본 상환 비축 |
기타 예비 | 바꿀 수있는 대출 어음 비축 |
번역 비축 |
누적 된 사상자 수 |
금액 | 비 - 제어 관심 |
금액 공평 | |
£'000 | £'000 | £'000 | £'000 | £'000 | £'000 | £'000 | £'000 | £'000 | £'000 | |
1에서 균형 일월 | ||||||||||
2023 | 6,990 | 33,672 | 17,476 | 527 | 82 | 168 | (56,566) | 2,349 | (121) | 2,228 |
Comprehensive | ||||||||||
오프 | ||||||||||
손실 기간 | - | - | - | - | - | - | (1,257) | (1,257) | (25) | (1,282) |
기타 포괄 손익 기간 | - | - | - | - | - | 5 | - | 5 | - | 5 |
금액 포괄적 인 | - | - | - | - | - | 5 | (1,257) | (1,252) | (25) | (1,277) |
에 대한 손실 year | ||||||||||
거래 내역 과 | ||||||||||
소유자 그룹 | ||||||||||
발행주식수 ...동안 | 214 | 2,171 | - | - | - | - | - | 2,385 | - | 2,385 |
전에, year | ||||||||||
발행물 경비 | - | (193) | - | - | - | - | - | (193) | - | (193) |
Transfers | - | - | - | (54) | - | - | 54 | - | - | - |
잔액 at 31 12월 2023 | 7,204 | 35,650 | 17,476 | 473 | 82 | 173 | (57,769) | 3,289 | (146) | 3,143 |
31월 XNUMX일로 종료하는 회계연도의 연결자본변동표 2022
주식 자본 |
프리미엄 공유 | 자본 상환 비축 |
기타 예비 | 바꿀 수있는 대출 어음 비축 |
번역 비축 |
누적 된 사상자 수 |
금액 | 비 - 제어 관심 금액 공평 | |
£'000 | £'000 | £'000 | £'000 | £'000 | £'000 | £'000 | £'000 | £'000 £'000 | |
1에서 균형 일월 | |||||||||
2022 | 5,849 | 33,502 | 17,476 | 573 | 82 | 133 | (55,588) | 2,027 | (125) 1,902 |
Comprehensive | |||||||||
오프 | |||||||||
손실 기간 | - | - | - | - | - | - | (1,149) | (1,149) | 4 (1,145) |
기타 포괄적 인 | - | - | - | - | - | 35 | - | 35 | 35 |
에 대한 소득 기간 | |||||||||
금액 포괄적 인 | - | - | - | - | - | 35 | (1,149) | (1,114) | 4 (1,110) |
에 대한 손실 year | |||||||||
거래 내역 과 | |||||||||
소유자 그룹 | |||||||||
발행주식수 ...동안 | 1,141 | 285 | - | - | - | - | - | 1,426 | - 1,426 |
전에, year | |||||||||
발행 비용 | (115) |
| (115) | (115) | |||||
주식결제형 형 주식 | - | - | - | 125 | - | - | - | 125 | - 125 |
기반으로 지불 | |||||||||
Transfers | - | - | - | (171) | - | - | 171 | - | - - |
잔액 at 31 12월 2022 | 6,990 | 33,672 | 17,476 | 527 | 82 | 168 | (56,566) | 2,349 | (121) 2,228 |
연결현금계산서 흐름 | ||
31월 XNUMX일로 종료되는 회계연도 2023 | ||
2023 £'000 |
2022 £'000 | |
영업현금흐름 방과 후 액티비티 | ||
이전 손실 과세 | (1,282) | (1,146) |
조정 용 : | ||
재무 비용 | 230 | 199 |
재산, 식물의 감가상각 장비 | 110 | 88 |
무형자산 상각 자산 | 23 | 40 |
재산, 식물 및 장비 처분 손실 | 11 | - |
Write off of research and development projects not taken forward | 141 | - |
전환대출어음 수정이익 | (89) | - |
비상임이사 수수료 | 91 | - |
주식 기준 지불 비용 | - | 125 |
기타 이득 | (83) | (71) |
환율의 영향 변동 | 5 | 35 |
(843) | (730) | |
Decrease/(Increase) in 재고품 | 105 | (48) |
Decrease/(Increase) in trade and other 채권 | 332 | (57) |
(Decrease)Increase in trade and other 미지급금 | (691) | 306 |
Decrease in staff advances | 15 | - |
증가하는 식량 | 7 | 7 |
에 사용한 순현금 운영 | (1,075) | (522) |
관심 지급 | (191) | (153) |
RDEC taxes 접수 | 71 | 69 |
영업에 사용된 순현금 방과 후 액티비티 | (1,195) | (606) |
투자로 인한 현금 흐름 방과 후 액티비티 | ||
부동산, 식물 구입 및 장비 | (9) | (70) |
Capitalised development expenditure (net of 보조금) | (361) | (674) |
투자에 사용 된 순 현금 방과 후 액티비티 | (370) | (744) |
Cash flows from / (used in) financing 방과 후 액티비티 | ||
Issue of ordinary share 자본 | 1,887 | 1,340 |
Expenses in connection with share 발행물 | (193) | (115) |
Net movement in invoice discount 시설 | (106) | (17) |
대기 대출 시설 반환 | - | (500) |
대기 대출 시설 drawdown | 250 | 750 |
주요 임대 결제 | (52) | (45) |
자금조달로 발생한 순현금 방과 후 액티비티 | 1,786 | 1,413 |
현금 및 현금의 순증가/감소 등가물 | 221 | 63 |
기초시점의 현금및현금등가물 기간 | 471 | 413 |
Exchange loss on cash and cash 등가물 | 13 | (5) |
기말 현금 및 현금등가물 기간 | 705 | 471 |
1. 재무정보의 성격
31년 2023월 2023일에 종료된 연도에 대한 요약 재무 정보가 포함된 이 결과 요약은 영국에서 채택된 국제 회계 기준. 연결재무제표는 역사적원가협약 및 계속기업기준에 따라 작성되었습니다.
본 문서에 포함된 재무 정보는 회사법 434('법') 2006조의 의미 내에서 법정 계정을 구성하지 않습니다. 31년 2022월 31일에 종료된 연도의 법정 계정은 회사 등록 기관에 제출되었으며, 2023년 XNUMX월 XNUMX일에 종료된 연도의 법정 계정은 연례 총회 이후 회사 등록 기관에 제출될 것입니다. 해당 법정 계정에 대한 독립 감사인의 보고서는 자격이 없었고 강조를 통해 어떤 문제에도 주의를 끌지 않았으며 법의 498(2) 또는 (3)항에 따른 진술을 포함하지 않았습니다. The report for year ended 31 December 2022 of the independent auditor on those statutory accounts was unqualified, did not draw attention to any matters by way of emphasis and did not contain a statement under section 498(2) or (3) of the Act.
2. 회계정책
그룹의 주요 회계 정책은 그룹의 연차 보고서 및 회계 2023에서 확인할 수 있습니다.
관심가는
그룹은 운영 현금 흐름, 송장 할인 시설 및 필요한 경우 추가 자금 조달을 통해 일상적인 운전 자본 요구 사항을 충족합니다.
The Directors have reviewed detailed budgets and forecasts until 30 June 2025 that were prepared by the Group. This review indicates that the Group is expected to continue trading as a going concern based on projected net cash flows derived from revenue generated by the Group. As a result of the Group's restructuring which took place in 2023, the Group's cost base has been reduced to a level appropriate for the current revenues of the Group.
이사들은 그룹이 예측 가능한 미래 동안 계속 운영할 수 있는 적절한 자원을 보유할 것이라고 믿을 만한 합리적인 근거가 있으므로 계속기업을 기준으로 재무제표를 작성하는 것이 적절하다고 생각합니다.
3. 매출 및 EBITDA
31 월 XNUMX 일 종료 연도 2023
프로브 | 직접 시장 모니터 |
기타 | 간접 시장 프로브 모니터 |
기타 |
금액 | |
£'000 | £'000 | £'000 | £'000 £'000 | £'000 | £'000 | |
UK | 394 | 113 | 42 | - - | - | 549 |
USA | 287 | 20 | 40 | - - | - | 347 |
프랑스 | - | - | - | 283 - | 2 | 285 |
포르투갈 | - | - | - | 185 - | - | 185 |
라틴어 아메리카 | - | - | - | 91 16 | - | 107 |
스칸디나비아 | - | - | - | 64 4 | 1 | 69 |
홍콩 홍콩 | - | - | - | 6 62 | - | 68 |
남쪽 대한민국 | - | - | - | 47 5 | 4 | 56 |
기타 국가 | 10 | 6 | 3 | 56 32 | 4 | 111 |
691 | 139 | 85 | 732 119 | 11 | 1,776 |
31 월 XNUMX 일 종료 연도 2022
직접 시장 간접적 인 시장
프로브 | 모니터 | 기타 | 프로브 | 모니터 | 기타 | 금액 | |
£'000 | £'000 | £'000 | £'000 | £'000 | £'000 | £'000 | |
UK | 461 | 106 | 75 | - | - | - | 642 |
USA | 463 | 122 | 51 | - | - | - | 636 |
프랑스 | - | - | - | 464 | 15 | 8 | 487 |
라틴 아메리카 | - | - | - | 90 | 212 | 2 | 304 |
남쪽 대한민국 | - | - | - | 132 | - | - | 132 |
香港 | - | - | - | 13 | 32 | 3 | 48 |
오스트리아 | - | - | - | 44 | - | 2 | 46 |
케이맨 제도 | - | - | - | 24 | 18 | 1 | 43 |
기타 국가 | 19 | 30 | - | 90 | 2 | 3 | 144 |
943 | 258 | 126 | 857 | 279 | 19 | 2,482 |
상품 판매와 서비스 제공으로 구분된 연결실체의 수익은 아래와 같습니다. 재화의 판매로 인한 모든 수익은 한 시점에 인식됩니다. 유지보수수익은 용역을 수행한 시점에 인식합니다.
2023 £'000 | 2022 £'000 | |
판매 상품 | 1,732 | 2,430 |
유지보수 수입 | 44 | 52 |
1,776 | 2,482 |
The reconciliation of the profit measure used by the Group's CODM to the result reported in the 여러 떼
consolidated SOCI is set out 아래 :
2023 £'000 | 2022 £'000 | |
조정 EBITDA 비현금 항목 : | (860) | (607) |
재산, 식물의 감가상각 장비 | (110) | (88) |
Amortisation of development 비용 | (23) | (40) |
Impairment loss on trade 채권 | - | (39) |
Non-executive directors' fees and employer's NIC | (91) | (136) |
전환사채 차익 | 89 | - |
Write off of research and development projects not taken forward | (141) | - |
주식 기준 지불 경비 | - | (125) |
Change in accumulated absence cost liability Cash item: | 1 | 17 |
기타 세금 수입 | 83 | 71 |
(192) | (340) | |
운영 오프 | (1,052) | (947) |
재무 비용 | (230) | (199) |
이전 손실 세 | (1,282) | (1,146) |
Tax credit on 오프 | - | 1 |
손실 year | (1,282) | (1,145) |
고객과의 계약에 따른 매출채권 및 계약부채에 대한 정보는 다음 표와 같습니다. 31년 2023월 31일 또는 2022년 XNUMX월 XNUMX일에 계약 자산이 없습니다.
31 XNUMX월 | 31 XNUMX월 | |
2023 | 2022 | |
£'000 | £'000 | |
Trade receivables which are in 'Trade and other 미수금' | 177 | 456 |
Contract liabilities (Note 17.3) | (44) | (39) |
31년 2023월 XNUMX일 기준으로 충족되지 않았거나 부분적으로 충족되지 않은 기존 계약의 이행 의무와 관련된 거래 가격의 합계 금액은 다음과 같습니다.
2024 | 2025 | 2026 | 2027 | 금액 | |
£'000 | £'000 | £'000 | £'000 | £'000 | |
Revenue expected to be 인정받은 | 31 | 4 | 2 | 7 | 44 |
Revenue recognised in 2023 which was included in contract liabilities at 31 December 2022 amounted 에
£24,000. Revenue recognised in 2022 included in contract liabilities at 31 December 2021 amounted to £ 30,000.
4. 배당금
이사는 배당(2022년: 없음) 지급을 권고할 수 없습니다.
5. 기본 및 희석주당손실
The loss per share calculation is based on the loss of £1,257,000 and the weighted average number of shares in issue of 1,181,214,755. For 2022, the loss per share calculation is based on the loss of £1,149,000 and the weighted average number of shares in issue of 685,490,974. While the Group is loss-making, the diluted loss per share and the loss per share are the same.
연차보고서 및 결산 배포
그룹은 곧 주주들에게 31년 2023월 11.00일에 종료되는 연차 보고서 및 계정 사본을 게시할 예정이며, 8년 2024월 25일 오전 4시에 DAC Beachcroft LLP 사무실에서 열리는 연례 주주총회 통지도 게시할 예정입니다. 8 Walbrook, 런던, ECXNUMXN XNUMXAF.
연례 보고서 및 결산서 사본과 연례 총회 통지문도 곧 그룹 웹사이트(www.deltexmedical.com)에서 제공될 예정입니다./investor-relations/
RNS는 귀하의 IP 주소를 사용하여 약관 준수 여부를 확인하고, 귀하가 이 커뮤니케이션에 포함된 정보를 사용하는 방식을 분석하고, 그러한 분석을 익명으로 다른 사람과 상용 서비스의 일부로 공유할 수 있습니다. RNS와 런던 증권 거래소가 귀하가 제공한 개인 데이터를 사용하는 방법에 대한 자세한 내용은 개인 정보 보호 정책을 참조하십시오.